With jobs data softening, inflation holding at 4.2% and the Federal Reserve sticking to higher rates for longer, investors are paying closer attention to sectors that may offer some relative stability. Healthcare stocks sit squarely in that conversation, especially large, well-rated companies from the Healthcare Stocks screener that are directly exposed to these macro shifts. This article breaks down three healthcare stocks that appear positively linked to the recent news, explaining why the current mix of slower hiring, steady inflation and a more unpredictable Fed may matter for their businesses and how that could inform your own watchlist decisions.

Arcutis Biotherapeutics (ARQT)

Overview: Arcutis Biotherapeutics is a biopharmaceutical company that develops and sells treatments for chronic skin conditions such as plaque psoriasis, atopic dermatitis and seborrheic dermatitis, led by its non steroidal topical drug ZORYVE. It also has earlier stage programs like ARQ-234 that target immune pathways involved in inflammatory skin disease.

Operations: Arcutis Biotherapeutics currently generates about US$415.6 million in revenue from developing and commercializing treatments for dermatological diseases.

Market Cap: US$3.2b

Arcutis Biotherapeutics provides direct exposure to prescription dermatology at a time when many other sectors are more sensitive to interest rates and the economic cycle. The investment story centers on ZORYVE, a non steroidal cream already approved across multiple psoriasis and pediatric atopic dermatitis indications, addressing tens of millions of potential patients and supported by recent FDA decisions, guideline endorsements and a virtual health platform that aims to widen access. Recent results show revenue of US$105.4 million in Q1 2026 and a much smaller loss of US$11.3 million. The key risk is that Arcutis remains loss making and relies on external funding, so execution on growth and cash flow is important from here.

Arcutis Biotherapeutics has a fast developing dermatology story, but the real hinge for investors is how that revenue base and funding needs fit together. Get the fuller picture with the Arcutis Biotherapeutics financial position in focus by reviewing the Arcutis Biotherapeutics financial health report.

Natera (NTRA)

Overview: Natera is a diagnostics company that uses molecular and genetic testing to help doctors detect, monitor and manage disease, from cancer recurrence with its Signatera and Latitude tests to prenatal screening, transplant rejection and kidney disease through platforms like Panorama, Prospera and Renasight.

Operations: Natera generates about US$2.5b in revenue primarily from the development and commercialization of molecular testing services, with most sales coming from the United States.

Market Cap: US$40.0b

Natera sits at the intersection of resilient healthcare demand and growing use of molecular diagnostics. This can look relatively appealing when higher interest rates are pressuring more cyclical sectors. Its Signatera platform is gaining real world traction, backed by NCCN guideline inclusion, Japan’s first MRD approval for colorectal cancer and multiple pharma collaborations that deepen its role in treatment decisions. At the same time, Natera is still loss making, funding is reliant on external sources and recent insider selling plus a rich P/S multiple point to valuation and governance questions. For investors who want to understand whether the growth in oncology, organ health and prenatal testing fairly compensates for those risks, this is a company worth looking at more closely.

Natera’s accelerating test adoption, rich P/S multiple and insider selling leave a key question hanging, and the quickest way to size up the growth versus valuation tension is the analyst forecasts for Natera

ADMA Biologics (ADMA)

Overview: ADMA Biologics develops, manufactures and sells plasma-derived therapies used to treat immune deficiencies and certain infectious disease exposures, including its BIVIGAM and ASCENIV intravenous immunoglobulin products and Nabi-HB for hepatitis B, supported by a network of plasma collection centers.

Operations: ADMA Biologics generates about US$493.0 million from ADMA Biomanufacturing, US$16.7 million from Plasma Collection Centers and a small US$0.1 million from unallocated license revenues.

Market Cap: US$2.1b

ADMA Biologics provides exposure to plasma-based therapies that tend to see steady medical need regardless of jobs data or rate moves. This is one reason healthcare is holding up while more rate-sensitive sectors come under pressure. The company is already profitable, with a 32.4% net margin and 42.4% ROE, and the recent FDA expansion of ASCENIV into younger pediatric patients widens its addressable pool of primary immunodeficiency cases. At the same time, ADMA relies on a relatively narrow product set and external borrowing, and it now faces a federal securities lawsuit over alleged revenue inflation and controls, which could weigh on sentiment. For investors weighing strong fundamentals against concentrated product risk and governance questions, there is more to consider in ADMA’s story than the headlines suggest.

ADMA Biologics’ strong margins and ROE raise the question of what the market might still be missing around its concentrated product mix and funding needs, so it is worth studying the analysis report for ADMA Biologics for the twist that could change the story.

The three healthcare stocks covered here are just a starting point, as the full Healthcare Stocks screener surfaces 29 more large, well-rated healthcare companies across providers, pharmaceuticals and medical devices with equally compelling stories. Use Simply Wall St to identify and analyze the specific catalysts, financial traits and risk profiles that match your thesis so you can focus on the highest conviction opportunities in this sector.

Take Control of Your Investment Journey

If Natera or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Beyond These Healthcare Stocks?

Fresh ideas often move first. By the time everyone else notices, the most attractive entry points can be gone. Scan curated stock lists before momentum is fully recognized and consider acting while opportunities are still developing.

• Spot smaller companies where strong balance sheets and fundamentals could support the next breakout phase by running the list of solid balance sheet and fundamentals (47 results).
• Track high yield opportunities that might pay you while you wait for sentiment to shift by reviewing the carefully filtered 7 dividend fortresses.
• Find under the radar stories with resilient business quality by checking the curated 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.